Design, synthesis and study of inhibitors of tryptophan 2,3-dioxygenase (TDO), a promising target for cancer therapy

Laurence Moineaux, Caroline Charlier, Eduard Dolusic, Pierre Larrieu, Luc Pilotte, Didier Colau, Vincent Stroobant, Moreno Galleni, Bernard Masereel, Benoît Van den Eynde, Johan Wouters (Promoteur), Raphaël Frédérick

Résultats de recherche: Contribution à un événement scientifique (non publié)Poster

Résumé

Immunotherapy is a promising novel strategy for cancer therapy. It consists of the therapeutic vaccination of cancer patients to stimulate their (natural) immune system against cancer cells. This approach, however, showed limited efficacy in vivo. Cancer cells are actually able to develop enzymatic mechanisms allowing tumours to resist or escape the immune rejection. Among the enzymes involved, the indoleamine 2,3-dioxygenases IDO and TDO represents potential actors. These enzymes catalyse the rapid degradation of tryptophan (Trp) through the kynurenine (KYN) pathway to form quinolinic acid (QA). This results in a local Trp depletion that severely affects the proliferation of T lymphocytes and is thereby profoundly immunosuppressive. This project was funded in part by Télévie (FNRS grant 7.4.543.07) and led in collaboration with the team of Pr Benoit Van Den Eynde (LICR, UCL) and Pr Moreno Galleni (CIP, ULG) aims at developing novel TDO inhibitors using a rational approach. These inhibitors will allow a better understanding of the role of TDO in the phenomenon of immunosuppression, especially in cancerous tumors. A series of vinyl-1H-indoles has been synthesized and their inhibitory potential has been evaluated on TDO of Ralstonia metallidurans (rmTDO) overexpressed in E.coli and purified by affinity chromatography. Crystallographic structure of some analogues was obtained and used as starting point for a docking study of these inhibitors in a model of humanized rmTDO. These data allowbetter understanding of how this family of inhibitors interact with TDO. This process is presented on this poster.
langue originaleAnglais
PagesAbstracts, école doctorale SFMBBM, Liège, Belgium, 10 December 2010
Nombre de pages1
étatPublié - 2010
Evénementécole doctorale Structure et Fonction des Macromolécules Biologiques, Bioinformatique et Modélisation (SFMBBM) - Liège, Belgique
Durée: 10 oct. 2010 → …

Réunion

Réunionécole doctorale Structure et Fonction des Macromolécules Biologiques, Bioinformatique et Modélisation (SFMBBM)
PaysBelgique
La villeLiège
période10/10/10 → …

Empreinte digitale

Tryptophan Oxygenase
Neoplasms
Tryptophan
Ralstonia
Therapeutics
Indoleamine-Pyrrole 2,3,-Dioxygenase
Quinolinic Acid
Kynurenine
Indoles
Posters
Organized Financing
Enzymes
Immunosuppressive Agents
Affinity Chromatography
Immunotherapy
Immunosuppression
Immune System
Vaccination
Escherichia coli
T-Lymphocytes

Citer ceci

Moineaux, L., Charlier, C., Dolusic, E., Larrieu, P., Pilotte, L., Colau, D., ... Frédérick, R. (2010). Design, synthesis and study of inhibitors of tryptophan 2,3-dioxygenase (TDO), a promising target for cancer therapy. Abstracts, école doctorale SFMBBM, Liège, Belgium, 10 December 2010. Poster présenté � école doctorale Structure et Fonction des Macromolécules Biologiques, Bioinformatique et Modélisation (SFMBBM), Liège, Belgique.
Moineaux, Laurence ; Charlier, Caroline ; Dolusic, Eduard ; Larrieu, Pierre ; Pilotte, Luc ; Colau, Didier ; Stroobant, Vincent ; Galleni, Moreno ; Masereel, Bernard ; Van den Eynde, Benoît ; Wouters, Johan ; Frédérick, Raphaël. / Design, synthesis and study of inhibitors of tryptophan 2,3-dioxygenase (TDO), a promising target for cancer therapy. Poster présenté � école doctorale Structure et Fonction des Macromolécules Biologiques, Bioinformatique et Modélisation (SFMBBM), Liège, Belgique.1 p.
@conference{81cca143330143c29fdd779e8103cfc9,
title = "Design, synthesis and study of inhibitors of tryptophan 2,3-dioxygenase (TDO), a promising target for cancer therapy",
abstract = "Immunotherapy is a promising novel strategy for cancer therapy. It consists of the therapeutic vaccination of cancer patients to stimulate their (natural) immune system against cancer cells. This approach, however, showed limited efficacy in vivo. Cancer cells are actually able to develop enzymatic mechanisms allowing tumours to resist or escape the immune rejection. Among the enzymes involved, the indoleamine 2,3-dioxygenases IDO and TDO represents potential actors. These enzymes catalyse the rapid degradation of tryptophan (Trp) through the kynurenine (KYN) pathway to form quinolinic acid (QA). This results in a local Trp depletion that severely affects the proliferation of T lymphocytes and is thereby profoundly immunosuppressive. This project was funded in part by T{\'e}l{\'e}vie (FNRS grant 7.4.543.07) and led in collaboration with the team of Pr Benoit Van Den Eynde (LICR, UCL) and Pr Moreno Galleni (CIP, ULG) aims at developing novel TDO inhibitors using a rational approach. These inhibitors will allow a better understanding of the role of TDO in the phenomenon of immunosuppression, especially in cancerous tumors. A series of vinyl-1H-indoles has been synthesized and their inhibitory potential has been evaluated on TDO of Ralstonia metallidurans (rmTDO) overexpressed in E.coli and purified by affinity chromatography. Crystallographic structure of some analogues was obtained and used as starting point for a docking study of these inhibitors in a model of humanized rmTDO. These data allowbetter understanding of how this family of inhibitors interact with TDO. This process is presented on this poster.",
keywords = "immunosuppression, therapeutic vaccination, cancer, Ralstonia metallidurans, kynurenine , tryptophan 2 3-dioxygenase",
author = "Laurence Moineaux and Caroline Charlier and Eduard Dolusic and Pierre Larrieu and Luc Pilotte and Didier Colau and Vincent Stroobant and Moreno Galleni and Bernard Masereel and {Van den Eynde}, Beno{\^i}t and Johan Wouters and Rapha{\"e}l Fr{\'e}d{\'e}rick",
year = "2010",
language = "English",
pages = "Abstracts, {\'e}cole doctorale SFMBBM, Li{\`e}ge, Belgium, 10 December 2010",
note = "{\'e}cole doctorale Structure et Fonction des Macromol{\'e}cules Biologiques, Bioinformatique et Mod{\'e}lisation (SFMBBM) ; Conference date: 10-10-2010",

}

Moineaux, L, Charlier, C, Dolusic, E, Larrieu, P, Pilotte, L, Colau, D, Stroobant, V, Galleni, M, Masereel, B, Van den Eynde, B, Wouters, J & Frédérick, R 2010, 'Design, synthesis and study of inhibitors of tryptophan 2,3-dioxygenase (TDO), a promising target for cancer therapy' école doctorale Structure et Fonction des Macromolécules Biologiques, Bioinformatique et Modélisation (SFMBBM), Liège, Belgique, 10/10/10, p. Abstracts, école doctorale SFMBBM, Liège, Belgium, 10 December 2010.

Design, synthesis and study of inhibitors of tryptophan 2,3-dioxygenase (TDO), a promising target for cancer therapy. / Moineaux, Laurence; Charlier, Caroline; Dolusic, Eduard; Larrieu, Pierre; Pilotte, Luc; Colau, Didier; Stroobant, Vincent; Galleni, Moreno; Masereel, Bernard; Van den Eynde, Benoît; Wouters, Johan (Promoteur); Frédérick, Raphaël.

2010. Abstracts, école doctorale SFMBBM, Liège, Belgium, 10 December 2010 Poster présenté � école doctorale Structure et Fonction des Macromolécules Biologiques, Bioinformatique et Modélisation (SFMBBM), Liège, Belgique.

Résultats de recherche: Contribution à un événement scientifique (non publié)Poster

TY - CONF

T1 - Design, synthesis and study of inhibitors of tryptophan 2,3-dioxygenase (TDO), a promising target for cancer therapy

AU - Moineaux, Laurence

AU - Charlier, Caroline

AU - Dolusic, Eduard

AU - Larrieu, Pierre

AU - Pilotte, Luc

AU - Colau, Didier

AU - Stroobant, Vincent

AU - Galleni, Moreno

AU - Masereel, Bernard

AU - Van den Eynde, Benoît

AU - Frédérick, Raphaël

A2 - Wouters, Johan

PY - 2010

Y1 - 2010

N2 - Immunotherapy is a promising novel strategy for cancer therapy. It consists of the therapeutic vaccination of cancer patients to stimulate their (natural) immune system against cancer cells. This approach, however, showed limited efficacy in vivo. Cancer cells are actually able to develop enzymatic mechanisms allowing tumours to resist or escape the immune rejection. Among the enzymes involved, the indoleamine 2,3-dioxygenases IDO and TDO represents potential actors. These enzymes catalyse the rapid degradation of tryptophan (Trp) through the kynurenine (KYN) pathway to form quinolinic acid (QA). This results in a local Trp depletion that severely affects the proliferation of T lymphocytes and is thereby profoundly immunosuppressive. This project was funded in part by Télévie (FNRS grant 7.4.543.07) and led in collaboration with the team of Pr Benoit Van Den Eynde (LICR, UCL) and Pr Moreno Galleni (CIP, ULG) aims at developing novel TDO inhibitors using a rational approach. These inhibitors will allow a better understanding of the role of TDO in the phenomenon of immunosuppression, especially in cancerous tumors. A series of vinyl-1H-indoles has been synthesized and their inhibitory potential has been evaluated on TDO of Ralstonia metallidurans (rmTDO) overexpressed in E.coli and purified by affinity chromatography. Crystallographic structure of some analogues was obtained and used as starting point for a docking study of these inhibitors in a model of humanized rmTDO. These data allowbetter understanding of how this family of inhibitors interact with TDO. This process is presented on this poster.

AB - Immunotherapy is a promising novel strategy for cancer therapy. It consists of the therapeutic vaccination of cancer patients to stimulate their (natural) immune system against cancer cells. This approach, however, showed limited efficacy in vivo. Cancer cells are actually able to develop enzymatic mechanisms allowing tumours to resist or escape the immune rejection. Among the enzymes involved, the indoleamine 2,3-dioxygenases IDO and TDO represents potential actors. These enzymes catalyse the rapid degradation of tryptophan (Trp) through the kynurenine (KYN) pathway to form quinolinic acid (QA). This results in a local Trp depletion that severely affects the proliferation of T lymphocytes and is thereby profoundly immunosuppressive. This project was funded in part by Télévie (FNRS grant 7.4.543.07) and led in collaboration with the team of Pr Benoit Van Den Eynde (LICR, UCL) and Pr Moreno Galleni (CIP, ULG) aims at developing novel TDO inhibitors using a rational approach. These inhibitors will allow a better understanding of the role of TDO in the phenomenon of immunosuppression, especially in cancerous tumors. A series of vinyl-1H-indoles has been synthesized and their inhibitory potential has been evaluated on TDO of Ralstonia metallidurans (rmTDO) overexpressed in E.coli and purified by affinity chromatography. Crystallographic structure of some analogues was obtained and used as starting point for a docking study of these inhibitors in a model of humanized rmTDO. These data allowbetter understanding of how this family of inhibitors interact with TDO. This process is presented on this poster.

KW - immunosuppression

KW - therapeutic vaccination

KW - cancer

KW - Ralstonia metallidurans

KW - kynurenine

KW - tryptophan 2 3-dioxygenase

M3 - Poster

SP - Abstracts, école doctorale SFMBBM, Liège, Belgium, 10 December 2010

ER -

Moineaux L, Charlier C, Dolusic E, Larrieu P, Pilotte L, Colau D et al.. Design, synthesis and study of inhibitors of tryptophan 2,3-dioxygenase (TDO), a promising target for cancer therapy. 2010. Poster présenté � école doctorale Structure et Fonction des Macromolécules Biologiques, Bioinformatique et Modélisation (SFMBBM), Liège, Belgique.